THOUSAND OAKS, Calif. , July 21, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for RepathaTM (evolocumab), the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in the world, for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol (LDL-C) reduction. Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver’s ability to remove LDL-C, or “bad” cholesterol, from the blood.1 Elevated LDL-C is an abnormality of cholesterol and/or fats in the blood,2,3 and is recognized as a major risk factor for cardiovascular disease (CVD).4,5
KalVista Pharmaceuticals Raises $33 Million to Advance Development of Novel Plasma Kallikrein Inhibitors in Diabetic Macular Edema and Hereditary Angioedema
BOSTON, Massachusetts and SALISBURY, England, July 22, 2015 /PRNewswire/ –KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE). Alongside the existing investors, Novo A/S and SV Life Sciences, the round included additional international healthcare investors experienced in plasma kallikrein targeted mechanisms led by RA Capital Management and including Longwood Fund and Venrock.
Propeller Health Receives FDA Clearance for the Propeller Platform in Association with Boehringer Ingelheim’s Respimat® Inhaler and GlaxoSmithKline’s Diskus® Inhaler
MADISON, Wis., July 22, 2015 /PRNewswire/ — Propeller Health, the FDA-cleared digital health solution for chronic respiratory disease, today announced U.S. Food and Drug Administration 510(k) clearance to market its Propeller platform in association with medications using GlaxoSmithKline’s Diskus® dry powder inhaler (DPI) device for asthma and chronic obstructive pulmonary disease (COPD). This new clearance follows 510(k) clearance to market the Propeller platform in association with medications using Boehringer Ingelheim’s Respimat® inhaler for chronic obstructive pulmonary disease (COPD) received in March 2015. read more
Anthelio Healthcare Solutions Acquires Pyramid Healthcare Solutions, Positioning Anthelio As The Largest Independent Provider Of Health Information Management Services
Acquisition unites two HIM industry leaders, opening new markets and enhancing services for Anthelio and Pyramid customers DALLAS–(EON: Enhanced Online News)–Anthelio Healthcare Solutions, the largest independent provider of healthcare technology and services, today announced it has acquired Pyramid Healthcare Solutions, an Avantha Group company, a leading provider of Health Information Management (HIM) and Revenue Cycle Services (RCM). The acquisition positions Anthelio to be the market leader in HIM and RCM services. It also expands Anthelio’s footprint in the patient financial services arena and enhances its revenue cycle offerings. Pyramid brings a full suite of revenue cycle management solutions and expertise to the relationship, as well as an established customer base of healthcare facilities. read more